{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:29:58Z","timestamp":1795130998510,"version":"4.10.3"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To inform recommendations by the Canadian Task Force on Preventive Health Care, we reviewed evidence on the benefits, harms, and acceptability of screening and treatment, and on the accuracy of risk prediction tools for the primary prevention of fragility fractures among adults aged 40 years and older in primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For screening effectiveness, accuracy of risk prediction tools, and treatment benefits, our search methods involved integrating studies published up to 2016 from an existing systematic review. Then, to locate more recent studies and any evidence relating to acceptability and treatment harms, we searched online databases (2016 to April 4, 2022 [screening] or to June 1, 2021 [predictive accuracy]; 1995 to June 1, 2021, for acceptability; 2016 to March 2, 2020, for treatment benefits; 2015 to June 24, 2020, for treatment harms), trial registries and gray literature, and hand-searched reviews, guidelines, and the included studies. Two reviewers selected studies, extracted results, and appraised risk of bias, with disagreements resolved by consensus or a third reviewer. The overview of reviews on treatment harms relied on one reviewer, with verification of data by another reviewer to correct errors and omissions. When appropriate, study results were pooled using random effects meta-analysis; otherwise, findings were described narratively. Evidence certainty was rated according to the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 4 randomized controlled trials (RCTs) and 1 controlled clinical trial (CCT) for the benefits and harms of screening, 1 RCT for comparative benefits and harms of different screening strategies, 32 validation cohort studies for the calibration of risk prediction tools (26 of these reporting on the Fracture Risk Assessment Tool without [i.e., clinical FRAX], or with the inclusion of bone mineral density (BMD) results [i.e., FRAX + BMD]), 27 RCTs for the benefits of treatment, 10 systematic reviews for the harms of treatment, and 12 studies for the acceptability of screening or initiating treatment.<\/jats:p>\n                    <jats:p>\n                      In females aged 65 years and older who are willing to independently complete a mailed fracture risk questionnaire (referred to as \u201cselected population\u201d), 2-step screening using a risk assessment tool with or without measurement of BMD probably (\n                      <jats:italic>moderate certainty<\/jats:italic>\n                      ) reduces the risk of hip fractures (3 RCTs and 1 CCT,\n                      <jats:italic>n<\/jats:italic>\n                      = 43,736, absolute risk reduction [ARD] = 6.2 fewer in 1000, 95% CI 9.0\u20132.8 fewer, number needed to screen [NNS] = 161) and clinical fragility fractures (3 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 42,009, ARD = 5.9 fewer in 1000, 95% CI 10.9\u20130.8 fewer, NNS = 169). It probably does not reduce all-cause mortality (2 RCTs and 1 CCT,\n                      <jats:italic>n<\/jats:italic>\n                      = 26,511, ARD = no difference in 1000, 95% CI 7.1 fewer to 5.3 more) and may (\n                      <jats:italic>low certainty<\/jats:italic>\n                      ) not affect health-related quality of life. Benefits for fracture outcomes were not replicated in an offer-to-screen population where the rate of response to mailed screening questionnaires was low. For females aged 68\u201380 years, population screening may not reduce the risk of hip fractures (1 RCT,\n                      <jats:italic>n<\/jats:italic>\n                      = 34,229, ARD = 0.3 fewer in 1000, 95% CI 4.2 fewer to 3.9 more) or clinical fragility fractures (1 RCT,\n                      <jats:italic>n<\/jats:italic>\n                      = 34,229, ARD = 1.0 fewer in 1000, 95% CI 8.0 fewer to 6.0 more) over 5 years of follow-up. The evidence for serious adverse events among all patients and for all outcomes among males and younger females (&lt;65 years) is very uncertain. We defined overdiagnosis as the identification of high risk in individuals who, if not screened, would never have known that they were at risk and would never have experienced a fragility fracture.\u00a0This was not directly reported in any of the trials. Estimates using data available in the trials suggest that among \u201cselected\u201d females\n                      <jats:italic>offered<\/jats:italic>\n                      screening, 12% of those meeting age-specific treatment thresholds based on clinical FRAX 10-year hip fracture risk, and 19% of those meeting thresholds based on clinical FRAX 10-year major osteoporotic fracture risk, may be overdiagnosed as being at high risk of fracture. Of those identified as being at high clinical FRAX 10-year hip fracture risk and who were\n                      <jats:italic>referred for BMD assessment<\/jats:italic>\n                      , 24% may be overdiagnosed. One RCT (\n                      <jats:italic>n<\/jats:italic>\n                      = 9268) provided evidence comparing 1-step to 2-step screening among postmenopausal females, but the evidence from this trial was very uncertain.\n                    <\/jats:p>\n                    <jats:p>\n                      For the calibration of risk prediction tools, evidence from three Canadian studies (\n                      <jats:italic>n<\/jats:italic>\n                      = 67,611) without serious risk of bias concerns indicates that clinical FRAX-Canada may be well calibrated for the 10-year prediction of hip fractures (observed-to-expected fracture ratio [O:E] = 1.13, 95% CI 0.74\u20131.72,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 89.2%), and is probably well calibrated for the 10-year prediction of clinical fragility fractures (O:E = 1.10, 95% CI 1.01\u20131.20,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 50.4%), both leading to some underestimation of the observed risk. Data from these same studies (\n                      <jats:italic>n<\/jats:italic>\n                      = 61,156) showed that FRAX-Canada with BMD may perform poorly to estimate 10-year hip fracture risk (O:E = 1.31, 95% CI 0.91-2.13,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 92.7%), but is probably well calibrated for the 10-year prediction of clinical fragility fractures, with some underestimation of the observed risk (O:E 1.16, 95% CI 1.12\u20131.20,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). The Canadian Association of Radiologists and Osteoporosis Canada Risk Assessment (CAROC) tool may be well calibrated to predict a category of risk for 10-year clinical fractures (low, moderate, or high risk; 1 study,\n                      <jats:italic>n<\/jats:italic>\n                      = 34,060). The evidence for most other tools was limited, or in the case of FRAX tools calibrated for countries other than Canada, very uncertain due to serious risk of bias concerns and large inconsistency in findings across studies.\n                    <\/jats:p>\n                    <jats:p>\n                      Postmenopausal females in a primary prevention population defined as &lt;50% prevalence of prior fragility fracture (median 16.9%, range 0 to 48% when reported in the trials) and at risk of fragility fracture, treatment with bisphosphonates as a class (median 2 years, range 1\u20136 years) probably reduces the risk of clinical fragility fractures (19 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 22,482, ARD = 11.1 fewer in 1000, 95% CI 15.0\u20136.6 fewer, [number needed to treat for an additional beneficial outcome] NNT = 90), and may reduce the risk of hip fractures (14 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 21,038, ARD = 2.9 fewer in 1000, 95% CI 4.6\u20130.9 fewer, NNT = 345) and clinical vertebral fractures (11 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 8921, ARD = 10.0 fewer in 1000, 95% CI 14.0\u20133.9 fewer, NNT = 100); it may not reduce all-cause mortality. There is low certainty evidence of little-to-no reduction in hip fractures with any individual bisphosphonate, but all provided evidence of decreased risk of clinical fragility fractures (moderate certainty for alendronate [NNT=68] and zoledronic acid [NNT=50], low certainty for risedronate [NNT=128]) among postmenopausal females. Evidence for an impact on risk of clinical vertebral fractures is very uncertain for alendronate and risedronate; zoledronic acid may reduce the risk of this outcome (4 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 2367, ARD = 18.7 fewer in 1000, 95% CI 25.6\u20136.6 fewer, NNT = 54) for postmenopausal females. Denosumab probably reduces the risk of clinical fragility fractures (6 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 9473, ARD = 9.1 fewer in 1000, 95% CI 12.1\u20135.6 fewer, NNT = 110) and clinical vertebral fractures (4 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 8639, ARD = 16.0 fewer in 1000, 95% CI 18.6\u201312.1 fewer, NNT=62), but may make little-to-no difference in the risk of hip fractures among postmenopausal females. Denosumab probably makes little-to-no difference in the risk of all-cause mortality or health-related quality of life among postmenopausal females. Evidence in males is limited to two trials (1 zoledronic acid, 1 denosumab); in this population, zoledronic acid may make little-to-no difference in the risk of hip or clinical fragility fractures, and evidence for all-cause mortality is very uncertain. The evidence for treatment with denosumab in males is very uncertain for all fracture outcomes (hip, clinical fragility, clinical vertebral) and all-cause mortality.\n                    <\/jats:p>\n                    <jats:p>\n                      There is moderate certainty evidence that treatment causes a small number of patients to experience a non-serious adverse event, notably non-serious gastrointestinal events (e.g., abdominal pain, reflux) with alendronate (50 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 22,549, ARD = 16.3 more in 1000, 95% CI 2.4\u201331.3 more, [number needed to treat for an additional harmful outcome] NNH = 61) but not with risedronate; influenza-like symptoms with zoledronic acid (5 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 10,695, ARD = 142.5 more in 1000, 95% CI 105.5\u2013188.5 more, NNH = 7); and non-serious gastrointestinal adverse events (3 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 8454, ARD = 64.5 more in 1000, 95% CI 26.4\u201313.3 more, NNH = 16), dermatologic adverse events (3 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 8454, ARD = 15.6 more in 1000, 95% CI 7.6\u201327.0 more, NNH = 64), and infections (any severity; 4 RCTs,\n                      <jats:italic>n<\/jats:italic>\n                      = 8691, ARD = 1.8 more in 1000, 95% CI 0.1\u20134.0 more, NNH = 556) with denosumab. For serious adverse events overall and specific to stroke and myocardial infarction, treatment with bisphosphonates probably makes little-to-no difference; evidence for other specific serious harms was less certain or not available. There was low certainty evidence for an increased risk for the rare occurrence of atypical femoral fractures (0.06 to 0.08 more in 1000) and osteonecrosis of the jaw (0.22 more in 1000) with bisphosphonates (most evidence for alendronate). The evidence for these rare outcomes and for rebound fractures with denosumab was very uncertain.\n                    <\/jats:p>\n                    <jats:p>Younger (lower risk) females have high willingness to be screened. A minority of postmenopausal females at increased risk for fracture may accept treatment. Further, there is large heterogeneity in the level of risk at which patients may be accepting of initiating treatment, and treatment effects appear to be overestimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      An offer of 2-step screening with risk assessment and BMD measurement to\n                      <jats:italic>selected<\/jats:italic>\n                      postmenopausal females with low prevalence of prior fracture probably results in a small reduction in the risk of clinical fragility fracture and hip fracture compared to no screening. These findings were most applicable to the use of clinical FRAX for risk assessment and were not replicated in the\n                      <jats:italic>offer-to-screen<\/jats:italic>\n                      population where the rate of response to mailed screening questionnaires was low. Limited direct evidence on harms of screening were available; using study data to provide estimates, there may be a moderate degree of overdiagnosis of high risk for fracture to consider. The evidence for younger females and males is very limited. The benefits of screening and treatment need to be weighed against the potential for harm; patient views on the acceptability of treatment are highly variable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>International Prospective Register of Systematic Reviews (PROSPERO): CRD42019123767.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-023-02181-w","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:13:37Z","timestamp":1679379217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools"],"prefix":"10.1186","volume":"12","author":[{"given":"Michelle","family":"Gates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-7229","authenticated-orcid":false,"given":"Jennifer","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Nuspl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aireen","family":"Wingert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hartling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"issue":"3","key":"2181_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11914-011-0060-5","volume":"9","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Schousboe JT. A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep. 2011;9(3):129\u201340.","journal-title":"Curr Osteoporos Rep."},{"issue":"9321","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929\u201336.","journal-title":"Lancet."},{"issue":"4","key":"2181_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.3636","volume":"34","author":"CJ Crandall","year":"2019","unstructured":"Crandall CJ, Larson J, Manson JE, Cauley JA, LaCroix AZ, Wactawski-Wende J, et al. A comparison of US and Canadian osteoporosis screening and treatment strategies in postmenopausal women. J Bone Miner Res. 2019;34(4):607\u201315.","journal-title":"J Bone Miner Res."},{"key":"2181_CR4","first-page":"20","volume":"20","author":"T Merlijn","year":"2019","unstructured":"Merlijn T, Swart KMA, van Schoor NM, Heymans MW, van der Zwaard BC, van der Heijden AA, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res. 2019;20:20.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","volume":"29","author":"KH Rubin","year":"2018","unstructured":"Rubin KH, Rothmann MJ, Holmberg T, Hoiberg M, Moller S, Barkmann R, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int. 2018;29(3):567\u201378.","journal-title":"Osteoporos Int."},{"issue":"10122","key":"2181_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741\u20137.","journal-title":"Lancet."},{"issue":"2","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","volume":"31","author":"T Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020;31(2):251\u20137.","journal-title":"Osteoporos Int."},{"issue":"4","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.carj.2011.05.001","volume":"62","author":"B Lentle","year":"2011","unstructured":"Lentle B, Cheung AM, Hanley DA, Leslie WD, Lyons D, Papaioannou A, et al. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J. 2011;62(4):243\u201350.","journal-title":"Can Assoc Radiol J."},{"issue":"2","key":"2181_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cger.2014.01.001","volume":"30","author":"SM Friedman","year":"2014","unstructured":"Friedman SM, Mendelson DA. Epidemiology of fragility fractures. Clin Geriatr Med. 2014;30(2):175\u201381.","journal-title":"Clin Geriatr Med."},{"issue":"10","key":"2181_CR10","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1359\/jbmr.080515","volume":"23","author":"EV McCloskey","year":"2008","unstructured":"McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A, Bonnet N, et al. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res. 2008;23(10):1561\u20138.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2181_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/jbmr.2204","volume":"29","author":"SN Morin","year":"2014","unstructured":"Morin SN, Lix LM, Leslie WD. The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res. 2014;29(7):1675\u201380.","journal-title":"J Bone Miner Res."},{"issue":"20","key":"2181_CR12","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/archinte.168.20.2261","volume":"168","author":"AB Hodsman","year":"2008","unstructured":"Hodsman AB, Leslie WD, Tsang JF, Gamble GD. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the manitoba bone density program. Arch Intern Med. 2008;168(20):2261\u20137.","journal-title":"Arch Intern Med."},{"key":"2181_CR13","doi-asserted-by":"publisher","first-page":"b4229","DOI":"10.1136\/bmj.b4229","volume":"339","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229.","journal-title":"BMJ."},{"issue":"20","key":"2181_CR14","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1001\/jama.298.20.2389","volume":"298","author":"J Robbins","year":"2007","unstructured":"Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007;298(20):2389\u201398.","journal-title":"JAMA."},{"key":"2181_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bone.2014.10.026","volume":"71","author":"JC Prior","year":"2015","unstructured":"Prior JC, Langsetmo L, Lentle BC, Berger C, Goltzman D, Kovacs CS, et al. Ten-year incident osteoporosis-related fractures in the population-based Canadian Multicentre Osteoporosis Study\u2014comparing site and age-specific risks in women and men. Bone. 2015;71:237\u201343.","journal-title":"Bone."},{"issue":"4","key":"2181_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/BOR.0000000000000400","volume":"29","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL. Osteoporosis in premenopausal women. Curr Opin Rheumatol. 2017;29(4):410\u20135.","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"2181_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ecl.2016.09.007","volume":"46","author":"A Cohen","year":"2017","unstructured":"Cohen A. Premenopausal osteoporosis. Endocrinol Metab Clin North Am. 2017;46(1):117\u201333.","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2181_CR18","unstructured":"World Health Organization. WHO Technical Report Series: assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994."},{"key":"2181_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2017.01.024","volume":"104","author":"EM Curtis","year":"2017","unstructured":"Curtis EM, Moon RJ, Harvey NC, Cooper C. The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone. 2017;104:29\u201338.","journal-title":"Bone."},{"issue":"9","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Od\u00e9n","year":"2015","unstructured":"Od\u00e9n A, McCloskey EV, Kanis JA, Harvey NC, Johansson H. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int. 2015;26(9):2243\u20138.","journal-title":"Osteoporos Int."},{"key":"2181_CR21","unstructured":"Public Health Agency of Canada. Public Health Infobase: Canadian Chronic Disease Indicators. Ottawa: PHAC; 2018."},{"issue":"9","key":"2181_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4065\/mcp.2010.0082","volume":"85","author":"JD Adachi","year":"2010","unstructured":"Adachi JD, Adami S, Gehlbach S, Anderson FA, Boonen S, Chapurlat RD, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010;85(9):806\u201313.","journal-title":"Mayo Clin Proc."},{"issue":"5","key":"2181_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009;181(5):265\u201371.","journal-title":"CMAJ."},{"issue":"5","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00198-008-0743-7","volume":"20","author":"A Papaioannou","year":"2009","unstructured":"Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009;20(5):703\u201314.","journal-title":"Osteoporos Int."},{"issue":"11","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s00198-012-1931-z","volume":"23","author":"JE Tarride","year":"2012","unstructured":"Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD, Papaioannou A, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int. 2012;23(11):2591\u2013600.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0969-8043(98)00026-8","volume":"50","author":"CF Njeh","year":"1999","unstructured":"Njeh CF, Fuerst T, Hans D, Blake GM, Genant HK. Radiation exposure in bone mineral density assessment. Appl Radiat Isot. 1999;50(1):215\u201336.","journal-title":"Appl Radiat Isot."},{"issue":"1","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12905-017-0377-z","volume":"17","author":"CA Hansen","year":"2017","unstructured":"Hansen CA, Abrahamsen B, Konradsen H, Pedersen BD. Women\u2019s lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. BMC Womens Health. 2017;17(1):17.","journal-title":"BMC Womens Health."},{"issue":"1","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-016-0286-z","volume":"11","author":"KL Barker","year":"2016","unstructured":"Barker KL, Toye F, Lowe CJM. A qualitative systematic review of patients\u2019 experience of osteoporosis using meta-ethnography. Arch Osteoporos. 2016;11(1):33.","journal-title":"Arch Osteoporos."},{"issue":"12","key":"2181_CR29","doi-asserted-by":"publisher","first-page":"e0208251","DOI":"10.1371\/journal.pone.0208251","volume":"13","author":"LM Hayawi","year":"2018","unstructured":"Hayawi LM, Graham ID, Tugwell P, Yousef AS. Screening for osteoporosis: a systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines. PLoS one. 2018;13(12):e0208251.","journal-title":"PLoS one."},{"issue":"17","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1503\/cmaj.100771","volume":"182","author":"A Papaioannou","year":"2010","unstructured":"Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864\u201373.","journal-title":"CMAJ."},{"issue":"24","key":"2181_CR31","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"United States Preventive Services Task Force","year":"2018","unstructured":"United States Preventive Services Task Force. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521\u201331.","journal-title":"JAMA."},{"issue":"3","key":"2181_CR32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","volume":"13","author":"North American Menopause Society","year":"2006","unstructured":"North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause (New York, NY). 2006;13(3):340.","journal-title":"Menopause (New York, NY)."},{"issue":"4","key":"2181_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.carj.2013.07.006","volume":"64","author":"K Siminoski","year":"2013","unstructured":"Siminoski K, O'Keeffe M, Brown JP, Burrell S, Coupland D, Dumont M, et al. Canadian Association of Radiologists technical standards for bone mineral densitometry reporting. Can Assoc Radiol J. 2013;64(4):281\u201394.","journal-title":"Can Assoc Radiol J."},{"key":"2181_CR34","unstructured":"The International Society for Clinical Densitometry. ISCD official position: Adults 2015 [Available from: https:\/\/www.iscd.org\/official-positions\/2015-iscd-official-positions-adult\/]."},{"issue":"6","key":"2181_CR35","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802\u201322.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2181_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jbmr.1956","volume":"28","author":"KH Rubin","year":"2013","unstructured":"Rubin KH, Friis-Holmberg T, Hermann AP, Abrahamsen B, Brixen K. Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Miner Res. 2013;28(8):1701\u201317.","journal-title":"J Bone Miner Res."},{"issue":"24","key":"2181_CR37","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2018.6537","volume":"319","author":"M Viswanathan","year":"2018","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(24):2532\u201351.","journal-title":"JAMA."},{"issue":"10","key":"2181_CR38","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","volume":"11","author":"KGM Moons","year":"2014","unstructured":"Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: The CHARMS checklist. PLOS Med. 2014;11(10):e1001744.","journal-title":"PLOS Med."},{"issue":"1","key":"2181_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV. A systematic review of intervention thresholds based on FRAX : a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.","journal-title":"Arch Osteoporos."},{"issue":"3","key":"2181_CR40","first-page":"178","volume":"56","author":"K Siminoski","year":"2005","unstructured":"Siminoski K, Leslie WD, Frame H, Hodsman A, Josse RG, Khan A, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J. 2005;56(3):178\u201388.","journal-title":"Can Assoc Radiol J."},{"issue":"10","key":"2181_CR41","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359\u201381.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.","journal-title":"Arch Osteoporos."},{"key":"2181_CR43","volume-title":"Lebanese FRAX-Based Osteoporosis Guidelines","author":"M Chakhtoura","year":"2013","unstructured":"Chakhtoura M, Baddoura R, El-Hajj Fuleihan G. Lebanese FRAX-Based Osteoporosis Guidelines 2013 [Available from: http:\/\/www.osteos.org.lb\/admin\/uploads\/Full%20document.pdf]."},{"issue":"1","key":"2181_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3\u201344.","journal-title":"Osteoporos Int."},{"key":"2181_CR45","volume-title":"Institute for Clinical Systems Improvement: diagnosis and treatment of osteoporosis","author":"J Beithon","year":"2017","unstructured":"Beithon J, Gallenberg M, Johnson K, Kildahl P, Krenik J, Liebow M, et al. Institute for Clinical Systems Improvement: diagnosis and treatment of osteoporosis 2017 [Available from: https:\/\/www.icsi.org\/guidelines__more\/catalog_guidelines_and_more\/catalog_guidelines\/catalog_womens_health_guidelines\/osteoporosis\/]."},{"issue":"5","key":"2181_CR46","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab."},{"issue":"s4","key":"2181_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161435.GL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142016. Endocr Pract. 2016;22(s4):1\u201342.","journal-title":"Endocr Pract."},{"issue":"11","key":"2181_CR48","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea M, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818\u201339.","journal-title":"Ann Intern Med."},{"key":"2181_CR49","volume-title":"Treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of a 2007 Report","author":"CJ Crandall","year":"2012","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Suttorp MJ, et al. Treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of a 2007 Report. Rockville: Agency for Healthcare Research and Quality; 2012."},{"issue":"11","key":"2181_CR50","first-page":"1178","volume":"23","author":"A Keshishian","year":"2017","unstructured":"Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, et al. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare Population. J Manag Care Spec Pharm. 2017;23(11):1178\u201390.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2181_CR51","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049.","journal-title":"BMJ Open."},{"issue":"9","key":"2181_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11926-015-0533-0","volume":"17","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Bours SPG, Boonen A. A review of patient preferences for osteoporosis drug treatment. Curr Rheumatol Rep. 2015;17(9):61.","journal-title":"Curr Rheumatol Rep."},{"key":"2181_CR53","doi-asserted-by":"crossref","unstructured":"Billington EO, Feasel AL, Kline GA. At odds about the odds: women\u2019s choices to accept osteoporosis medications do not closely agree with physician-set treatment thresholds. J Gen Intern Med. 2020;35(1):276-82.","DOI":"10.1007\/s11606-019-05384-x"},{"issue":"1","key":"2181_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13643-020-01572-7","volume":"10","author":"J Pillay","year":"2021","unstructured":"Pillay J, Riva JJ, Tessier LA, Colquhoun H, Lang E, Moore AE, et al. Fall prevention interventions for older community-dwelling adults: systematic reviews on benefits, harms, and patient values and preferences. Syst Rev. 2021;10(1):18.","journal-title":"Syst Rev."},{"issue":"1","key":"2181_CR55","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13643-019-1094-5","volume":"8","author":"M Gates","year":"2019","unstructured":"Gates M, Pillay J, Th\u00e9riault G, Limburg H, Grad R, Klarenbach S, et al. Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review. Syst Rev. 2019;8(1):216.","journal-title":"Syst Rev."},{"key":"2181_CR56","unstructured":"Canadian Task Force on Preventive Health Care. Procedure Manual 2014 [Available from: https:\/\/canadiantaskforce.ca\/methods\/]."},{"key":"2181_CR57","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"issue":"4","key":"2181_CR58","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395\u2013400.","journal-title":"J Clin Epidemiol."},{"key":"2181_CR59","doi-asserted-by":"publisher","unstructured":"Theriault G, Reynolds D, Pillay J, Limburg H, Grad R, Gates M, et al. Expanding the measurement of overdiagnosis in the context of disease precursors and risk factors. BMJ Evid Based Med. 2023;bmjebm-2022-112117. https:\/\/doi.org\/10.1136\/bmjebm-2022-112117.","DOI":"10.1136\/bmjebm-2022-112117"},{"key":"2181_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6537","volume-title":"Screening to prevent osteoporotic fractures: an evidence review for the US Preventive Services Task Force","author":"M Viswanathan","year":"2018","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: an evidence review for the US Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality; 2018."},{"key":"2181_CR61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","volume":"69","author":"P Whiting","year":"2016","unstructured":"Whiting P, Jelena S, Higgins LPT, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225\u201334.","journal-title":"J Clin Epidemiol."},{"key":"2181_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136.","journal-title":"J Clin Epidemiol."},{"key":"2181_CR63","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ."},{"issue":"1","key":"2181_CR64","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","volume":"170","author":"KM Moons","year":"2019","unstructured":"Moons KM, Wolff RF, Riley RD, et al. Probast: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1\u2013W33.","journal-title":"Ann Intern Med."},{"key":"2181_CR65","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ."},{"key":"2181_CR66","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jclinepi.2018.01.013","volume":"111","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Alonso-Coello P, Guyatt GH, Yepes-Nu\u00f1ez JJ, Akl EA, Hazlewood G, et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness. J Clin Epidemiol. 2019;111:94\u2013104.","journal-title":"J Clin Epidemiol."},{"issue":"3","key":"2181_CR67","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials."},{"issue":"3","key":"2181_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-142-3-200502010-00007","volume":"142","author":"LM Kern","year":"2005","unstructured":"Kern LM, Powe NR, Levine MA, Fitzpatrick AL, Harris TB, Robbins J, et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med. 2005;142(3):173\u201381.","journal-title":"Ann Intern Med."},{"issue":"9","key":"2181_CR69","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"M Sweeting","year":"2004","unstructured":"Sweeting M, Sutton A, Lambert P. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351\u201375.","journal-title":"Stat Med."},{"key":"2181_CR70","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 61, Cochrane","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Higgins J, Vist G, Glasziou P, Akl E, Skoetz N, et al. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Cochrane Handbook for Systematic Reviews of Interventions version 61, Cochrane; 2020."},{"key":"2181_CR71","volume-title":"Table 13-10-0710-01: Deaths and mortality rate, by age group","author":"Statistics Canada","year":"2018","unstructured":"Statistics Canada. Table 13-10-0710-01: Deaths and mortality rate, by age group 2018 [Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310071001]."},{"key":"2181_CR72","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 61: Cochrane","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Vist G, Higgins J, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Cochrane Handbook for Systematic Reviews of Interventions version 61: Cochrane; 2020."},{"issue":"4","key":"2181_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/M13-2886","volume":"160","author":"JE Cornell","year":"2014","unstructured":"Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014;160(4):267\u201370.","journal-title":"Ann Intern Med."},{"issue":"1","key":"2181_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.","journal-title":"BMC Med Res Methodol."},{"key":"2181_CR75","volume-title":"Development and application of statistical methods for prognosis research (Doctoral Thesis)","author":"KIE Snell","year":"2015","unstructured":"Snell KIE. Development and application of statistical methods for prognosis research (Doctoral Thesis): University of Birmingham; 2015. Available from: https:\/\/etheses.bham.ac.uk\/id\/eprint\/6259\/"},{"issue":"1","key":"2181_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2288-14-5","volume":"14","author":"D van Klaveren","year":"2014","unstructured":"van Klaveren D, Steyerberg EW, Perel P, Vergouwe Y. Assessing discriminative ability of risk models in clustered data. BMC Med Res Methodol. 2014;14(1):5.","journal-title":"BMC Med Res Methodol."},{"issue":"2","key":"2181_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0962280207087173","volume":"17","author":"G Qin","year":"2008","unstructured":"Qin G, Hotilovac L. Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test. Stat Methods Med Res. 2008;17(2):207\u201321.","journal-title":"Stat Methods Med Res."},{"key":"2181_CR78","volume-title":"Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme","author":"J Popay","year":"2006","unstructured":"Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme, 2006 [Available from: http:\/\/citeseerx.ist.psu.edu\/viewdoc\/download?doi=10.1.1.178.3100&rep=rep1&type=pdf]."},{"issue":"20","key":"2181_CR79","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357.","journal-title":"Stat Med."},{"issue":"12","key":"2181_CR80","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence\u2014imprecision. J Clin Epidemiol. 2011;64(12):1283\u201393.","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"2181_CR81","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness. J Clin Epidemiol. 2011;64(12):1303\u201310.","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"2181_CR82","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12):1294\u2013302.","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"2181_CR83","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias. J Clin Epidemiol. 2011;64(12):1277\u201382.","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2181_CR84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407\u201315.","journal-title":"J Clin Epidemiol."},{"issue":"7650","key":"2181_CR85","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ."},{"key":"2181_CR86","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","volume":"87","author":"M Hultcrantz","year":"2017","unstructured":"Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4\u201313.","journal-title":"J Clin Epidemiol."},{"issue":"3","key":"2181_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","volume":"22","author":"MH Murad","year":"2017","unstructured":"Murad MH, Mustafa RA, Sch\u00fcnemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85\u20137.","journal-title":"Evid Based Med."},{"key":"2181_CR88","doi-asserted-by":"publisher","first-page":"i6460","DOI":"10.1136\/bmj.i6460","volume":"356","author":"TPA Debray","year":"2017","unstructured":"Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.","journal-title":"BMJ."},{"key":"2181_CR89","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126\u201335.","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2181_CR90","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00198-009-1007-x","volume":"21","author":"RJ Barr","year":"2010","unstructured":"Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int. 2010;21(4):561\u20138.","journal-title":"Osteoporos Int."},{"issue":"6","key":"2181_CR91","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/jbmr.3411","volume":"33","author":"E McCloskey","year":"2018","unstructured":"McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res. 2018;33(6):1020\u20136.","journal-title":"J Bone Miner Res."},{"issue":"18","key":"2181_CR92","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1001\/archinte.1997.00440390121015","volume":"157","author":"DJ Torgerson","year":"1997","unstructured":"Torgerson DJ, Thomas RE, Campbell MK, Reid DM. Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med. 1997;157(18):2121\u20135.","journal-title":"Arch Intern Med."},{"issue":"3","key":"2181_CR93","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00005650-200503000-00012","volume":"43","author":"AZ Lacroix","year":"2005","unstructured":"Lacroix AZ, Buist DS, Brenneman SK, Abbott TA 3rd. Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. Med Care. 2005;43(3):293\u2013302.","journal-title":"Med Care."},{"issue":"9","key":"2181_CR94","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Od\u00e9n A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239\u201356.","journal-title":"Osteoporos Int."},{"issue":"3","key":"2181_CR95","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","volume":"1","author":"LP Fried","year":"1991","unstructured":"Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263\u201376.","journal-title":"Ann Epidemiol."},{"key":"2181_CR96","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1471-2474-13-204","volume":"13","author":"R Azagra","year":"2012","unstructured":"Azagra R, Roca G, Encabo G, Aguye A, Zwart M, Guell S, et al. FRAX(R) tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord. 2012;13:204.","journal-title":"BMC Musculoskelet Disord."},{"issue":"1","key":"2181_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medcli.2013.11.014","volume":"144","author":"R Azagra","year":"2015","unstructured":"Azagra R, Roca G, Martin-Sanchez JC, Casado E, Encabo G, Zwart M, et al. FRAX(R) thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population. Med Clin. 2015;144(1):1\u20138.","journal-title":"Med Clin."},{"key":"2181_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.maturitas.2015.10.002","volume":"83","author":"R Azagra","year":"2016","unstructured":"Azagra R, Zwart M, Aguye A, Martin-Sanchez JC, Casado E, Diaz-Herrera MA, et al. Fracture experience among participants from the FROCAT study: what thresholding is appropriate using the FRAX tool? Maturitas. 2016;83:65\u201371.","journal-title":"Maturitas."},{"key":"2181_CR99","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12891-016-1096-6","volume":"17","author":"R Azagra","year":"2016","unstructured":"Azagra R, Zwart M, Encabo G, Aguye A, Martin-Sanchez JC, Puchol-Ruiz N, et al. Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women. BMC Musculoskelet Disord. 2016;17:262.","journal-title":"BMC Musculoskelet Disord."},{"issue":"2","key":"2181_CR100","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jbmr.215","volume":"26","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res. 2011;26(2):420\u20137.","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2181_CR101","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamapsychiatry.2017.0449","volume":"74","author":"JM Bolton","year":"2017","unstructured":"Bolton JM, Morin SN, Majumdar SR, Sareen J, Lix LM, Johansson H, et al. Association of mental disorders and related medication use with risk for major osteoporotic fractures. JAMA Psychiatry. 2017;74(6):641\u20138.","journal-title":"JAMA Psychiatry."},{"issue":"1","key":"2181_CR102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00198-013-2525-0","volume":"25","author":"SL Brennan","year":"2014","unstructured":"Brennan SL, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, et al. FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos Int. 2014;25(1):61\u20139.","journal-title":"Osteoporos Int."},{"issue":"9","key":"2181_CR103","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/jbmr.3455","volume":"33","author":"B Buehring","year":"2018","unstructured":"Buehring B, Hansen KE, Lewis BL, Cummings SR, Lane NE, Binkley N, et al. Dysmobility syndrome independently increases fracture risk in the osteoporotic fractures in men (MrOS) prospective cohort study. J Bone Miner Res. 2018;33(9):1622\u20139.","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2181_CR104","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11606-018-4696-z","volume":"34","author":"CJ Crandall","year":"2019","unstructured":"Crandall CJ, Larson J, LaCroix A, Cauley JA, LeBoff MS, Li W, et al. Predicting fracture risk in younger postmenopausal women: comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study. J Gen Intern Med. 2019;34(2):235\u201342.","journal-title":"J Gen Intern Med."},{"issue":"12","key":"2181_CR105","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1210\/jc.2014-2332","volume":"99","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Larson JC, Watts NB, Gourlay ML, Donaldson MG, LaCroix A, et al. Comparison of fracture risk prediction by the US Preventive Services Task Force strategy and two alternative strategies in women 50-64 years old in the Women's Health Initiative. J Clin Endocrinol Metab. 2014;99(12):4514\u201322.","journal-title":"J Clin Endocrinol Metab."},{"key":"2181_CR106","first-page":"28","volume":"28","author":"CJ Crandall","year":"2019","unstructured":"Crandall CJ, Schousboe JT, Morin SN, Lix LM, Leslie W. Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: the Manitoba BMD Registry. J Bone Miner Res. 2019;28:28.","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2181_CR107","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5604\/15093492.1091517","volume":"15","author":"E Czerwinski","year":"2013","unstructured":"Czerwinski E, Borowy P, Kumorek A, Amarowicz J, Gorkiewicz M, Milert A. Fracture risk prediction in outpatients from Krakow Region using FRAX tool versus fracture risk in 11-year follow-up. Ortop Traumatol Rehabil. 2013;15(6):617\u201328.","journal-title":"Ortop Traumatol Rehabil."},{"key":"2181_CR108","doi-asserted-by":"publisher","first-page":"i6755","DOI":"10.1136\/bmj.i6755","volume":"356","author":"N Dagan","year":"2017","unstructured":"Dagan N, Cohen-Stavi C, Leventer-Roberts M, Balicer RD. External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study. BMJ. 2017;356:i6755.","journal-title":"BMJ."},{"issue":"4","key":"2181_CR109","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00198-012-2215-3","volume":"24","author":"B Ettinger","year":"2013","unstructured":"Ettinger B, Ensrud KE, Blackwell T, Curtis JR, Lapidus JA, Orwoll ES, et al. Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int. 2013;24(4):1185\u201393.","journal-title":"Osteoporos Int."},{"issue":"3","key":"2181_CR110","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jocd.2012.01.011","volume":"15","author":"B Ettinger","year":"2012","unstructured":"Ettinger B, Liu H, Blackwell T, Hoffman AR, Ensrud KE, Orwoll ES. Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study. J Clin Densitom. 2012;15(3):334\u201342.","journal-title":"J Clin Densitom."},{"issue":"3","key":"2181_CR111","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00198-010-1465-1","volume":"22","author":"LA Fraser","year":"2011","unstructured":"Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, et al. Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int. 2011;22(3):829\u201337.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR112","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/aje\/kwx128","volume":"187","author":"I Goldshtein","year":"2018","unstructured":"Goldshtein I, Gerber Y, Ish-Shalom S, Leshno M. Fracture risk assessment with FRAX using real-world data in a population-based cohort from Israel. Am J Epidemiol. 2018;187(1):94\u2013102.","journal-title":"Am J Epidemiol."},{"issue":"1","key":"2181_CR113","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11657-017-0389-1","volume":"12","author":"ML Gourlay","year":"2017","unstructured":"Gourlay ML, Ritter VS, Fine JP, Overman RA, Schousboe JT, Cawthon PM, et al. Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study. Arch Osteoporos. 2017;12(1):91.","journal-title":"Arch Osteoporos."},{"issue":"3","key":"2181_CR114","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jbmr.3331","volume":"33","author":"NC Harvey","year":"2018","unstructured":"Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, et al. Falls predict fractures independently of FRAX probability: a Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res. 2018;33(3):510\u20136.","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2181_CR115","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/jbmr.372","volume":"26","author":"TA Hillier","year":"2011","unstructured":"Hillier TA, Cauley JA, Rizzo JH, Pedula KL, Ensrud KE, Bauer DC, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res. 2011;26(8):1774\u201382.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2181_CR116","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00198-017-4226-6","volume":"29","author":"KL Holloway","year":"2018","unstructured":"Holloway KL, Mohebbi M, Betson AG, Hans D, Hyde NK, Brennan-Olsen SL, et al. Prediction of major osteoporotic and hip fractures in Australian men using FRAX scores adjusted with trabecular bone score. Osteoporos Int. 2018;29(1):101\u20138.","journal-title":"Osteoporos Int."},{"issue":"6","key":"2181_CR117","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00198-015-3092-3","volume":"26","author":"M Iki","year":"2015","unstructured":"Iki M, Fujita Y, Tamaki J, Kouda K, Yura A, Sato Y, et al. Trabecular bone score may improve FRAX(R) prediction accuracy for major osteoporotic fractures in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study. Osteoporos Int. 2015;26(6):1841\u20138.","journal-title":"Osteoporos Int."},{"key":"2181_CR118","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bone.2016.02.011","volume":"86","author":"J Kalvesten","year":"2016","unstructured":"Kalvesten J, Lui LY, Brismar T, Cummings S. Digital X-ray radiogrammetry in the study of osteoporotic fractures: Comparison to dual energy X-ray absorptiometry and FRAX. Bone. 2016;86:30\u20135.","journal-title":"Bone."},{"issue":"2","key":"2181_CR119","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.1503\/cmaj.100458","volume":"183","author":"L Langsetmo","year":"2011","unstructured":"Langsetmo L, Nguyen TV, Nguyen ND, Kovacs CS, Prior JC, Center JR, et al. Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. CMAJ. 2011;183(2):E107\u201314.","journal-title":"CMAJ."},{"issue":"7","key":"2181_CR120","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/jbmr.3433","volume":"33","author":"L Langsetmo","year":"2018","unstructured":"Langsetmo L, Peters KW, Burghardt AJ, Ensrud KE, Fink HA, Cawthon PM, et al. Volumetric bone mineral density and failure load of distal limbs predict incident clinical fracture independent HR-pQCT BMD and failure load predicts incident clinical fracture of FRAX and clinical risk factors among older men. J Bone Miner Res. 2018;33(7):1302\u201311.","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2181_CR121","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00198-010-1445-5","volume":"22","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, et al. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int. 2011;22(6):1873\u201383.","journal-title":"Osteoporos Int."},{"key":"2181_CR122","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11657-013-0145-0","volume":"8","author":"WD Leslie","year":"2013","unstructured":"Leslie WD, Brennan SL, Lix LM, Johansson H, Oden A, McCloskey E, et al. Direct comparison of eight national FRAX(R) tools for fracture prediction and treatment qualification in Canadian women. Arch Osteoporos. 2013;8:145.","journal-title":"Arch Osteoporos."},{"issue":"9","key":"2181_CR123","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00198-014-2761-y","volume":"25","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, et al. Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporos Int. 2014;25(9):2271\u20137.","journal-title":"Osteoporos Int."},{"issue":"2","key":"2181_CR124","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jocd.2010.02.002","volume":"13","author":"WD Leslie","year":"2010","unstructured":"Leslie WD, Lix LM. Simplified 10-Year Absolute Fracture Risk Assessment: A Comparison of Men and Women. J Clin Densitom. 2010;13(2):141\u20136.","journal-title":"J Clin Densitom."},{"issue":"11","key":"2181_CR125","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/jbmr.123","volume":"25","author":"WD Leslie","year":"2010","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350\u20138.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2181_CR126","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-011-1814-8","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. A comparative study of using non-hip bone density inputs with FRAX(R). Osteoporos Int. 2012;23(3):853\u201360.","journal-title":"Osteoporos Int."},{"issue":"11","key":"2181_CR127","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1210\/jc.2017-01327","volume":"102","author":"WD Leslie","year":"2017","unstructured":"Leslie WD, Lix LM, Majumdar SR, Morin SN, Johansson H, Oden A, et al. Total hip bone area affects fracture prediction with FRAX in Canadian white women. J Clin Endocrinol Metab. 2017;102(11):4242\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2181_CR128","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1007\/s00198-016-3613-8","volume":"27","author":"WD Leslie","year":"2016","unstructured":"Leslie WD, Majumdar SR, Lix LM, Josse RG, Johansson H, Oden A, et al. Direct comparison of FRAX(R) and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. Osteoporos Int. 2016;27(9):2689\u201395.","journal-title":"Osteoporos Int."},{"issue":"9","key":"2181_CR129","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00198-017-4091-3","volume":"28","author":"WD Leslie","year":"2017","unstructured":"Leslie WD, Majumdar SR, Morin SN, Lix LM, Johansson H, Oden A, et al. FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry. Osteoporos Int. 2017;28(9):2557\u201364.","journal-title":"Osteoporos Int."},{"issue":"3","key":"2181_CR130","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00198-018-4415-y","volume":"29","author":"WD Leslie","year":"2018","unstructured":"Leslie WD, Majumdar SR, Morin SN, Lix LM, Schousboe JT, Ensrud KE, et al. Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. Osteoporos Int. 2018;29(3):759\u201367.","journal-title":"Osteoporos Int."},{"issue":"3","key":"2181_CR131","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jocd.2011.04.010","volume":"14","author":"WD Leslie","year":"2011","unstructured":"Leslie WD, Morin S. Fracture burden in relation to low bone mineral density and FRAX((R)) probability. J Clin Densitom. 2011;14(3):279\u201385.","journal-title":"J Clin Densitom."},{"issue":"1","key":"2181_CR132","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00198-011-1747-2","volume":"23","author":"WD Leslie","year":"2012","unstructured":"Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012;23(1):75\u201385.","journal-title":"Osteoporos Int."},{"issue":"2","key":"2181_CR133","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1359\/jbmr.081012","volume":"24","author":"WD Leslie","year":"2009","unstructured":"Leslie WD, Tsang JF, Lix LM. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res. 2009;24(2):353\u201360.","journal-title":"J Bone Miner Res."},{"key":"2181_CR134","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bone.2015.04.028","volume":"77","author":"G Li","year":"2015","unstructured":"Li G, Thabane L, Papaioannou A, Adachi JD. Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures. Bone. 2015;77:107\u201314.","journal-title":"Bone."},{"issue":"1","key":"2181_CR135","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13104-018-3178-z","volume":"11","author":"LM Lix","year":"2018","unstructured":"Lix LM, Leslie WD, Majumdar SR. Measuring improvement in fracture risk prediction for a new risk factor: a simulation. BMC Res Notes. 2018;11(1):62.","journal-title":"BMC Res Notes."},{"issue":"3","key":"2181_CR136","first-page":"188","volume":"17","author":"JC Lo","year":"2011","unstructured":"Lo JC, Pressman AR, Chandra M, Ettinger B. Fracture risk tool validation in an integrated healthcare delivery system. Am J Manag Care. 2011;17(3):188\u201394.","journal-title":"Am J Manag Care."},{"issue":"11","key":"2181_CR137","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1210\/jc.2016-2569","volume":"101","author":"SR Majumdar","year":"2016","unstructured":"Majumdar SR, Leslie WD, Lix LM, Morin SN, Johansson H, Oden A, et al. Longer duration of diabetes strongly impacts fracture risk assessment: the Manitoba BMD Cohort. J Clin Endocrinol Metab. 2016;101(11):4489\u201396.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2181_CR138","doi-asserted-by":"publisher","first-page":"e000509","DOI":"10.1136\/rmdopen-2017-000509","volume":"3","author":"A Marques","year":"2017","unstructured":"Marques A, Lucas R, Simoes E, Verstappen SMM, Jacobs JWG, da Silva JAP. Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open. 2017;3(2):e000509.","journal-title":"RMD Open."},{"issue":"7","key":"2181_CR139","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/jbmr.3124","volume":"32","author":"P Martineau","year":"2017","unstructured":"Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, et al. Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD Cohort. J Bone Miner Res. 2017;32(7):1568\u201374.","journal-title":"J Bone Miner Res."},{"key":"2181_CR140","doi-asserted-by":"publisher","first-page":"528790","DOI":"10.1155\/2012\/528790","volume":"2012","author":"LJ Melton 3rd","year":"2012","unstructured":"Melton LJ 3rd, Atkinson EJ, Achenbach SJ, Kanis JA, Therneau TM, Johansson H, et al. Potential Extensions of the US FRAX Algorithm. J Osteoporos. 2012;2012:528790.","journal-title":"J Osteoporos."},{"issue":"3","key":"2181_CR141","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/jbmr.3021","volume":"32","author":"ES Orwoll","year":"2017","unstructured":"Orwoll ES, Lapidus J, Wang PY, Vandenput L, Hoffman A, Fink HA, et al. The limited clinical utility of testosterone, estradiol, and sex hormone binding globulin measurements in the prediction of fracture risk and bone loss in older men. J Bone Miner Res. 2017;32(3):633\u201340.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2181_CR142","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00198-015-3196-9","volume":"26","author":"W Pluskiewicz","year":"2015","unstructured":"Pluskiewicz W, Adamczyk P, Czekajlo A, Grzeszczak W, Drozdzowska B. High fracture probability predicts fractures in a 4-year follow-up in women from the RAC-OST-POL study. Osteoporos Int. 2015;26(12):2811\u201320.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR143","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jbmr.1729","volume":"28","author":"M Premaor","year":"2013","unstructured":"Premaor M, Parker RA, Cummings S, Ensrud K, Cauley JA, Lui LY, et al. Predictive value of FRAX for fracture in obese older women. J Bone Miner Res. 2013;28(1):188\u201395.","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2181_CR144","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jocd.2011.06.006","volume":"14","author":"AR Pressman","year":"2011","unstructured":"Pressman AR, Lo JC, Chandra M, Ettinger B. Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated health care delivery system. J Clin Densitom. 2011;14(4):407\u201315.","journal-title":"J Clin Densitom."},{"issue":"2","key":"2181_CR145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4321\/S1889-836X2017000200002","volume":"9","author":"AI Reyes Dominguez","year":"2017","unstructured":"Reyes Dominguez AI, Sosa Cabrera N, Saavedra Santana P, de Tejada Romero MJG, Jodar Gimeno E, Sosa HM. Assessment of the predictive capacity of the garvan calculator of 10 year risk of fracture in a Spanish population. Rev de Osteoporos Metab Miner. 2017;9(2):55\u201361.","journal-title":"Rev de Osteoporos Metab Miner."},{"issue":"10","key":"2181_CR146","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/jbmr.106","volume":"25","author":"E Sornay-Rendu","year":"2010","unstructured":"Sornay-Rendu E, Munoz F, Delmas PD, Chapurlat RD. The FRAX tool in French women: how well does it describe the real incidence of fracture in the OFELY cohort? J Bone Miner Res. 2010;25(10):2101\u20137.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2181_CR147","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s00198-011-1537-x","volume":"22","author":"J Tamaki","year":"2011","unstructured":"Tamaki J, Iki M, Kadowaki E, Sato Y, Kajita E, Kagamimori S, et al. Fracture risk prediction using FRAX(R): a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. Osteoporos Int. 2011;22(12):3037\u201345.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR148","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00774-018-0910-7","volume":"37","author":"J Tamaki","year":"2019","unstructured":"Tamaki J, Iki M, Sato Y, Winzenrieth R, Kajita E, Kagamimori S, et al. Does Trabecular Bone Score (TBS) improve the predictive ability of FRAX for major osteoporotic fractures according to the Japanese Population-Based Osteoporosis (JPOS) cohort study? J Bone Miner Metab. 2019;37(1):161\u201370.","journal-title":"J Bone Miner Metab."},{"issue":"6","key":"2181_CR149","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bone.2010.08.019","volume":"47","author":"S Tanaka","year":"2010","unstructured":"Tanaka S, Yoshimura N, Kuroda T, Hosoi T, Saito M, Shiraki M. The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women--A joint analysis of the Nagano, Miyama, and Taiji Cohorts. Bone. 2010;47(6):1064\u201370.","journal-title":"Bone."},{"issue":"2","key":"2181_CR150","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jocd.2012.05.007","volume":"16","author":"C Tebe Cordomi","year":"2013","unstructured":"Tebe Cordomi C, Del Rio LM, Di Gregorio S, Casas L, Estrada MD, Kotzeva A, et al. Validation of the FRAX predictive model for major osteoporotic fracture in a historical cohort of Spanish women. J Clin Densitom. 2013;16(2):231\u20137.","journal-title":"J Clin Densitom."},{"issue":"5","key":"2181_CR151","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jbmr.12","volume":"25","author":"FA Tremollieres","year":"2010","unstructured":"Tremollieres FA, Pouilles JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res. 2010;25(5):1002\u20139.","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2181_CR152","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00198-018-4780-6","volume":"30","author":"S Yang","year":"2019","unstructured":"Yang S, Leslie WD, Morin SN, Lix LM. Administrative healthcare data applied to fracture risk assessment. Osteoporos Int. 2019;30(3):565\u201371.","journal-title":"Osteoporos Int."},{"issue":"5","key":"2181_CR153","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/QAI.0000000000000998","volume":"72","author":"MT Yin","year":"2016","unstructured":"Yin MT, Shiau S, Rimland D, Gibert CL, Bedimo RJ, Rodriguez-Barradas MC, et al. Fracture prediction with Modified-FRAX in older HIV-infected and uninfected men. J Acquir Immune Defic Syndr. 2016;72(5):513\u201320.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"6","key":"2181_CR154","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/jbmr.3977","volume":"35","author":"L-C Desbiens","year":"2020","unstructured":"Desbiens L-C, Mac-Way F, Sidibe A, Beaudoin C, Jean S. Comparison of fracture prediction tools in individuals without and with early chronic kidney disease: a population-based analysis of CARTaGENE. J Bone Miner Res. 2020;35(6):1048\u201357.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2181_CR155","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/jbmr.3924","volume":"35","author":"R Chapurlat","year":"2020","unstructured":"Chapurlat R, Bui M, Sornay-Rendu E, Zebaze R, Delmas PD, Liew D, et al. Deterioration of cortical and trabecular microstructure identifies women with osteopenia or normal bone mineral density at imminent and long-term risk for fragility fracture: a prospective study. J Bone Miner Res. 2020;35(5):833\u201344.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2181_CR156","doi-asserted-by":"publisher","first-page":"E10239","DOI":"10.1002\/jbm4.10239","volume":"3","author":"CJ Crandall","year":"2019","unstructured":"Crandall CJ, Larson J, Cauley JA, Schousboe JT, LaCroix AZ, Robbins JA, et al. Do additional clinical risk factors improve the performance of fracture risk assessment tool (FRAX) among postmenopausal women? Findings from the Women's Health Initiative Observational Study and Clinical Trials. JBMR Plus. 2019;3(12):E10239.","journal-title":"JBMR Plus."},{"issue":"1","key":"2181_CR157","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41591-019-0720-z","volume":"26","author":"N Dagan","year":"2020","unstructured":"Dagan N, Elnekave E, Barda N, Bregman-Amitai O, Bar A, Orlovsky M, et al. Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization. Nat Med. 2020;26(1):77\u201382.","journal-title":"Nat Med."},{"key":"2181_CR158","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.bonr.2019.100223","volume":"11","author":"LLF de Abreu","year":"2019","unstructured":"de Abreu LLF, Holloway-Kew KL, Sajjad MA, Kotowicz MA, Pasco JA. FRAX (Australia) scores in women with impaired fasting glucose and diabetes. Bone Rep. 2019;11:100223.","journal-title":"Bone Rep."},{"issue":"4","key":"2181_CR159","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jbmr.4239","volume":"36","author":"NC Harvey","year":"2021","unstructured":"Harvey NC, Kanis JA, Liu E, Cooper C, Lorentzon M, Bea JW, et al. Predictive value of DXA appendicular lean mass for incident fractures, falls, and mortality, independent of prior falls, FRAX, and BMD: findings from the Women's Health Initiative (WHI). J Bone Miner Res. 2021;36(4):654\u201361.","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2181_CR160","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00198-019-05088-2","volume":"30","author":"KL Holloway-Kew","year":"2019","unstructured":"Holloway-Kew KL, Zhang Y, Betson AG, Anderson KB, Hans D, Hyde NK, et al. How well do the FRAX (Australia) and Garvan calculators predict incident fractures? Data from the Geelong Osteoporosis Study. Osteoporos Int. 2019;30(10):2129\u201339.","journal-title":"Osteoporos Int."},{"issue":"2","key":"2181_CR161","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3803\/EnM.2020.35.2.359","volume":"35","author":"H Kim","year":"2020","unstructured":"Kim H, Kim JH, Kim MJ, Hong AR, Choi H, Ku E, et al. Low predictive value of FRAX adjusted by trabecular bone score for osteoporotic fractures in Korean women: a community-based cohort study. Endocrinol Metab (Seoul, Korea). 2020;35(2):359\u201366.","journal-title":"Endocrinol Metab (Seoul, Korea)."},{"issue":"1","key":"2181_CR162","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13073-021-00838-6","volume":"13","author":"T Lu","year":"2021","unstructured":"Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, et al. Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Med. 2021;13(1):16.","journal-title":"Genome Med."},{"issue":"1","key":"2181_CR163","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1148\/radiol.2020200466","volume":"297","author":"PJ Pickhardt","year":"2020","unstructured":"Pickhardt PJ, Graffy PM, Zea R, Lee SJ, Liu J, Sandfort V, et al. Automated abdominal CT imaging biomarkers for opportunistic prediction of future major osteoporotic fractures in asymptomatic adults. Radiology. 2020;297(1):64\u201372.","journal-title":"Radiology."},{"issue":"10","key":"2181_CR164","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00198-021-05941-3","volume":"32","author":"W Pluskiewicz","year":"2021","unstructured":"Pluskiewicz W, Adamczyk P, Drozdzowska B. Height loss in postmenopausal women-do we need more for fracture risk assessment? Results from the GO Study. Osteoporos Int. 2021;32(10):2043\u20139.","journal-title":"Osteoporos Int."},{"issue":"6","key":"2181_CR165","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00223-021-00809-4","volume":"108","author":"X Xiao","year":"2021","unstructured":"Xiao X, Wu Q. The utility of genetic risk score to improve performance of FRAX for fracture prediction in US postmenopausal women. Calcif Tissue Int. 2021;108(6):746\u201356.","journal-title":"Calcif Tissue Int."},{"issue":"Suppl 1","key":"2181_CR166","first-page":"284","volume":"33","author":"EJ Bisson","year":"2018","unstructured":"Bisson EJ, Finlayson M, Ekuma O, Marrie RA, Leslie WD. Accuracy of FRAX in people with multiple sclerosis: a Manitoba BMD registry-based cohort study. J Bone Miner Res. 2018;33(Suppl 1):284.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2181_CR167","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11657-020-00735-2","volume":"15","author":"WD Leslie","year":"2020","unstructured":"Leslie WD, Lix LM, Binkley N. Targeted vertebral fracture assessment for optimizing fracture prevention in Canada. Arch Osteoporos. 2020;15(1):65.","journal-title":"Arch Osteoporos."},{"issue":"1","key":"2181_CR168","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11657-019-0660-8","volume":"15","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Binkley N. Comparison of treatment strategies and thresholds for optimizing fracture prevention in Canada: a simulation analysis. Arch Osteoporos. 2019;15(1):4.","journal-title":"Arch Osteoporos."},{"issue":"1","key":"2181_CR169","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11657-020-00763-y","volume":"15","author":"WD Leslie","year":"2020","unstructured":"Leslie WD, Morin SN, Lix LM, Binkley N. Impact of spine-hip discordance on fracture risk assessment and treatment qualification in Canada: the Manitoba BMD registry. Arch Osteoporos. 2020;15(1):85.","journal-title":"Arch Osteoporos."},{"issue":"11","key":"2181_CR170","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00198-019-05106-3","volume":"30","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, et al. Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporos Int. 2019;30(11):2195\u2013203.","journal-title":"Osteoporos Int."},{"issue":"6","key":"2181_CR171","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/jbmr.3971","volume":"35","author":"G Li","year":"2020","unstructured":"Li G, Leslie WD, Kovacs CS, Prior J, Josse RG, Towheed T, et al. Combining frailty and trabecular bone score did not improve predictive accuracy in risk of major osteoporotic fractures. J Bone Miner Res. 2020;35(6):1058\u201364.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2181_CR172","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archinte.163.7.789","volume":"163","author":"BH Ascott-Evans","year":"2003","unstructured":"Ascott-Evans BH, Gua\u00f1abens N, Kivinen S, Stuckey BGA, Magaril CH, Vandormael K, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003;163(7):789\u201394.","journal-title":"Arch Intern Med."},{"issue":"6","key":"2181_CR173","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1210\/jcem.87.6.8575","volume":"87","author":"NH Bell","year":"2002","unstructured":"Bell NH, Bilezikian JP, Bone Iii HG, Kaur A, Maragoto A, Santora AC. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab. 2002;87(6):2792\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2181_CR174","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149\u201357.","journal-title":"J Clin Endocrinol Metab."},{"issue":"18","key":"2181_CR175","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster J-Y, Kaufman J-M, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714\u201323.","journal-title":"N Engl J Med."},{"issue":"2","key":"2181_CR176","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"CH Chesnut","year":"1995","unstructured":"Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99(2):144\u201352.","journal-title":"Am J Med."},{"issue":"24","key":"2181_CR177","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077\u201382.","journal-title":"JAMA."},{"issue":"8","key":"2181_CR178","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med."},{"issue":"5","key":"2181_CR179","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000;85(5):1895\u2013900.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2181_CR180","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/jbmr.2009","volume":"29","author":"A Grey","year":"2014","unstructured":"Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, et al. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res. 2014;29(1):166\u201372.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2181_CR181","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/01.ogx.0000351672.54929.75","volume":"64","author":"A Grey","year":"2009","unstructured":"Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. Obstet Gynecol Surv. 2009;64(7):462\u20133.","journal-title":"Obstet Gynecol Surv."},{"issue":"3","key":"2181_CR182","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13697130500118126","volume":"8","author":"MJ Hooper","year":"2005","unstructured":"Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005;8(3):251\u201362.","journal-title":"Climacteric."},{"issue":"5","key":"2181_CR183","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1185\/030079903125002009","volume":"19","author":"D Hosking","year":"2003","unstructured":"Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin. 2003;19(5):383\u201394.","journal-title":"Curr Med Res Opin."},{"issue":"8","key":"2181_CR184","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJM199802193380801","volume":"338","author":"D Hosking","year":"1998","unstructured":"Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998;338(8):485\u201392.","journal-title":"N Engl J Med."},{"issue":"12","key":"2181_CR185","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832\u201341.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2181_CR186","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/BF02896007","volume":"25","author":"Y Li","year":"2005","unstructured":"Li Y, Zhang Z, Deng X, Chen L. Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. J Huazhong Univ Sci Technol Med Sci. 2005;25(5):527\u20139.","journal-title":"J Huazhong Univ Sci Technol Med Sci."},{"issue":"22","key":"2181_CR187","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Br\u00f6ll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333(22):1437\u201344.","journal-title":"N Engl J Med."},{"issue":"5","key":"2181_CR188","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009;114(5):999\u20131007.","journal-title":"Obstet Gynecol."},{"issue":"5","key":"2181_CR189","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333\u201340.","journal-title":"N Engl J Med."},{"issue":"2","key":"2181_CR190","first-page":"396","volume":"83","author":"L Mortensen","year":"1998","unstructured":"Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83(2):396\u2013402.","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2181_CR191","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2181_CR192","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/2230-8210.146871","volume":"19","author":"S Pitale","year":"2015","unstructured":"Pitale S, Thomas M, Rathi G, Deshmukh V, Kumar P, Reddy S, et al. A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian J Endocrinol Metab. 2015;19(1):148\u201354.","journal-title":"Indian J Endocrinol Metab."},{"issue":"5","key":"2181_CR193","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HAP Pols","year":"1999","unstructured":"Pols HAP, Felsenberg D, Hanley DA, \u0160tep\u00e1n J, Mu\u00f1oz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Osteoporos Int. 1999;9(5):461\u20138.","journal-title":"Osteoporos Int."},{"issue":"9","key":"2181_CR194","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653\u201361.","journal-title":"N Engl J Med."},{"issue":"25","key":"2181_CR195","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407\u201316.","journal-title":"N Engl J Med."},{"issue":"9","key":"2181_CR196","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.clinthera.2007.09.017","volume":"29","author":"MJ V\u00e4lim\u00e4iki","year":"2007","unstructured":"V\u00e4lim\u00e4iki MJ, Farrerons-Minguella J, Halse J, Kr\u00f6ger H, Maroni M, Mulder H, et al. Effects of risedronate 5 mg\/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 2007;29(9):1937\u201349.","journal-title":"Clin Ther."},{"issue":"4","key":"2181_CR197","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00774-009-0057-7","volume":"27","author":"Y Yan","year":"2009","unstructured":"Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, et al. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab. 2009;27(4):471\u20138.","journal-title":"J Bone Miner Metab."},{"key":"2181_CR198","unstructured":"Zhu HM, Tang H, Cheng Q, He L, Li PQ, Xue QY, et al. Efficacy and safety of denosumab in Chinese postmenopausal women with osteoporosis at increased risk of fracture: Results from a 12-month, randomized, double-blind, placebo-controlled phase III study. J Bone Miner Res. 2017;31(Suppl 1):S160."},{"issue":"6","key":"2181_CR199","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, T\u00f6rring O, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727\u201336.","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2181_CR200","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/jbmr.1625","volume":"27","author":"MG Donaldson","year":"2012","unstructured":"Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial. J Bone Miner Res. 2012;27(8):1804\u201310.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2181_CR201","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1210\/jc.2011-2081","volume":"97","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(1):286\u201392.","journal-title":"J Clin Endocrinol Metab."},{"issue":"36","key":"2181_CR202","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1503\/cmaj.161207","volume":"189","author":"A Grey","year":"2017","unstructured":"Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ. 2017;189(36):E1130\u2013E6.","journal-title":"CMAJ."},{"issue":"6","key":"2181_CR203","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1359\/JBMR.050104","volume":"20","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005;20(6):971\u20136.","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2181_CR204","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480\u20136.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2181_CR205","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, Boonen S, T\u00f6rring O, Roux C, Rizzoli R, Bone HG, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211\u20138.","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2181_CR206","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821\u201331.","journal-title":"N Engl J Med."},{"key":"2181_CR207","volume-title":"Denosumab China Phase III Study. Clincaltrials.gov","author":"NCT","year":"2016","unstructured":"NCT: Denosumab China Phase III Study. Clincaltrials.gov. 2016 [Available from: https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01479832\/full]."},{"issue":"4","key":"2181_CR208","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00198-011-1720-0","volume":"23","author":"S Silverman","year":"2012","unstructured":"Silverman S, Viswanathan HN, Yang YC, Wang A, Boonen S, Ragi-Eis S, et al. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int. 2012;23(4):1361\u20139.","journal-title":"Osteoporos Int."},{"issue":"5","key":"2181_CR209","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","volume":"101","author":"JR Tucci","year":"1996","unstructured":"Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101(5):488\u2013501.","journal-title":"Am J Med."},{"issue":"4","key":"2181_CR210","doi-asserted-by":"publisher","first-page":"E0123080","DOI":"10.1371\/journal.pone.0123080","volume":"10","author":"LX Chen","year":"2015","unstructured":"Chen LX, Ning GZ, Zhou ZR, Li YL, Zhang D, Wu QL, et al. The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. PLOS ONE. 2015;10(4):E0123080.","journal-title":"PLOS ONE."},{"issue":"10","key":"2181_CR211","doi-asserted-by":"publisher","first-page":"711","DOI":"10.7326\/M14-0317","volume":"161","author":"CJ Crandall","year":"2014","unstructured":"Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711\u201323.","journal-title":"Ann Intern Med."},{"issue":"78","key":"2181_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20780","volume":"20","author":"S Davis","year":"2016","unstructured":"Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess (Winchester, England). 2016;20(78):1\u2013406.","journal-title":"Health Technol Assess (Winchester, England)."},{"issue":"29","key":"2181_CR213","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","volume":"24","author":"S Davis","year":"2020","unstructured":"Davis S, Simpson E, Hamilton J, Martyn-St James M, Rawdin A, Wong R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess. 2020;24(29):1\u2013314.","journal-title":"Health Technol Assess."},{"issue":"6","key":"2181_CR214","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ando.2015.10.009","volume":"76","author":"D Diedhiou","year":"2015","unstructured":"Diedhiou D, Cuny T, Sarr A, Norou Diop S, Klein M, Weryha G. Efficacy and safety of denosumab for the treatment of osteoporosis: a systematic review. Ann Endocrinol. 2015;76(6):650\u20137.","journal-title":"Ann Endocrinol."},{"key":"2181_CR215","series-title":"Comparative Effectiveness Review, No. 18. Agency for Healthcare Research and Quality (US)","volume-title":"Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review","author":"HA Fink","year":"2019","unstructured":"Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, et al. Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review. Comparative Effectiveness Review, No. 18. Agency for Healthcare Research and Quality (US); 2019."},{"key":"2181_CR216","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","volume":"252","author":"G Kranenburg","year":"2016","unstructured":"Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, et al. Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis. 2016;252:106\u201315.","journal-title":"Atherosclerosis."},{"key":"2181_CR217","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone. 2020;130:115121.","journal-title":"Bone."},{"key":"2181_CR218","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body J-J, Rodriguez EG, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;dgaa756. https:\/\/doi.org\/10.1210\/clinem\/dgaa756.","DOI":"10.1210\/clinem\/dgaa756"},{"key":"2181_CR219","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"L Tripto-Shkolnik","year":"2020","unstructured":"Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I. Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone. 2020;130:115150.","journal-title":"Bone."},{"issue":"7","key":"2181_CR220","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00198-007-0535-5","volume":"19","author":"EW de Bekker-Grob","year":"2008","unstructured":"de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW. Patients\u2019 preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int. 2008;19(7):1029\u201337.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR221","first-page":"102","volume":"1","author":"LN Fuzzell","year":"2020","unstructured":"Fuzzell LN, Fraenkel L, Stark SL, Seehra SS, Nelson C, Keleman A, et al. A mixed methods study exploring older womens\u2019 attitudes toward osteoporosis medications: adapting a health communication framework. Womens Health Rep (New Rochelle, NY). 2020;1(1):102\u201313.","journal-title":"Womens Health Rep (New Rochelle, NY)."},{"issue":"6","key":"2181_CR222","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1370\/afm.1407","volume":"10","author":"B Hudson","year":"2012","unstructured":"Hudson B, Zarifeb A, Young L, Wells J. Patients\u2019 expectations of screening and preventive treatments. Ann Fam Med. 2012;10(6):495\u2013502.","journal-title":"Ann Fam Med."},{"issue":"3","key":"2181_CR223","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3899\/jrheum.130548","volume":"41","author":"JM Neuner","year":"2014","unstructured":"Neuner JM, Schapira MM. Patient perceptions of osteoporosis treatment thresholds. J Rheumatol. 2014;41(3):516\u201322.","journal-title":"J Rheumatol."},{"issue":"1","key":"2181_CR224","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11657-019-0624-z","volume":"14","author":"L Si","year":"2019","unstructured":"Si L, Tu L, Xie Y, Palmer AJ, Gu Y, Zheng X, et al. Chinese patients\u2019 preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment. Arch Osteoporos. 2019;14(1):85.","journal-title":"Arch Osteoporos."},{"issue":"5","key":"2181_CR225","doi-asserted-by":"publisher","first-page":"E0128063","DOI":"10.1371\/journal.pone.0128063","volume":"10","author":"A LeBlanc","year":"2015","unstructured":"LeBlanc A, Wang AT, Wyatt K, Branda ME, Shah ND, Van Houten H, et al. Encounter decision aid vs. clinical decision support or usual care to support patient-centered treatment decisions in osteoporosis: The Osteoporosis Choice Randomized Trial II. PLoS One. 2015;10(5):E0128063.","journal-title":"PLoS One."},{"issue":"6","key":"2181_CR226","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjmed.2011.01.013","volume":"124","author":"VM Montori","year":"2011","unstructured":"Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011;124(6):549\u201356.","journal-title":"Am J Med."},{"issue":"2","key":"2181_CR227","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00198-016-3767-4","volume":"28","author":"AJ Smallwood","year":"2017","unstructured":"Smallwood AJ, Schapira MM, Fedders M, Neuner JM. A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal. Osteoporos Int. 2017;28(2):567\u201376.","journal-title":"Osteoporos Int."},{"issue":"7","key":"2181_CR228","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00198-021-05823-8","volume":"32","author":"CS Liu","year":"2021","unstructured":"Liu CS, Feasel AL, Kline GA, Billington EO. Pharmacotherapy decisions among postmenopausal women attending a group medical consultation or a one-on-one specialist consultation at an osteoporosis center: an observational cohort study. Osteoporos Int. 2021;32(7):1421\u20137.","journal-title":"Osteoporos Int."},{"issue":"589","key":"2181_CR229","doi-asserted-by":"publisher","first-page":"E469","DOI":"10.3399\/bjgp11X588439","volume":"61","author":"B Hudson","year":"2011","unstructured":"Hudson B, Toop L, Mangin D, Pearson J. Risk communication methods in hip fracture prevention: a randomised trial in primary care. Br J Gen Pract. 2011;61(589):E469\u201376.","journal-title":"Br J Gen Pract."},{"issue":"2","key":"2181_CR230","doi-asserted-by":"publisher","first-page":"e013703","DOI":"10.1136\/bmjopen-2016-013703","volume":"7","author":"R Kalluru","year":"2017","unstructured":"Kalluru R, Petrie KJ, Grey A, Nisa Z, Horne AM, Gamble GD, et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open. 2017;7(2):e013703.","journal-title":"BMJ Open."},{"issue":"1","key":"2181_CR231","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamainternmed.2015.7339","volume":"176","author":"SL Sheridan","year":"2016","unstructured":"Sheridan SL, Sutkowi-Hemstreet A, Barclay C, Brewer NT, Dolor RJ, Gizlice Z, et al. A comparative effectiveness trial of alternate formats for presenting benefits and harms information for low-value screening services: a randomized clinical trial. JAMA Intern Med. 2016;176(1):31\u201341.","journal-title":"JAMA Intern Med."},{"issue":"12","key":"2181_CR232","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1007\/s00198-017-4205-y","volume":"28","author":"MJ Rothmann","year":"2017","unstructured":"Rothmann MJ, M\u00f6ller S, Holmberg T, H\u00f8jberg M, Gram J, Bech M, et al. Non-participation in systematic screening for osteoporosis\u2014the ROSE trial. Osteoporos Int. 2017;28(12):3389\u201399.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR233","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11657-014-0192-1","volume":"9","author":"MJ Rothmann","year":"2014","unstructured":"Rothmann MJ, Huniche L, Ammentorp J, Barkmann R, Gl\u00fcer CC, Hermann AP. Women\u2019s perspectives and experiences on screening for osteoporosis (Risk-stratified Osteoporosis Strategy Evaluation, ROSE). Arch Osteoporos. 2014;9(1):192.","journal-title":"Arch Osteoporos."},{"issue":"12","key":"2181_CR234","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015;30(12):2179\u201387.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2181_CR235","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/pubmed\/fdq050","volume":"33","author":"M Deutekom","year":"2011","unstructured":"Deutekom M, Vansenne F, McCaffery K, Essink-Bot M-L, Stronks K, Bossuyt PMM. The effects of screening on health behaviour: a summary of the results of randomized controlled trials. J Public Health. 2011;33(1):71\u20139.","journal-title":"J Public Health."},{"issue":"3","key":"2181_CR236","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00198-019-05270-6","volume":"31","author":"CI Condurache","year":"2020","unstructured":"Condurache CI, Chiu S, Chotiyarnwong P, Johansson H, Shepstone L, Lenaghan E, et al. Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporos Int. 2020;31(3):457\u201364.","journal-title":"Osteoporos Int."},{"issue":"3","key":"2181_CR237","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jocd.2011.05.010","volume":"14","author":"T Masud","year":"2011","unstructured":"Masud T, Binkley N, Boonen S, Hannan MT. Official Positions for FRAX\u00ae clinical regarding falls and frailty: can falls and frailty be used in FRAX\u00ae? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX\u00ae. J Clin Densitometry. 2011;14(3):194\u2013204.","journal-title":"J Clin Densitometry"},{"issue":"1","key":"2181_CR238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-011-9544-7","volume":"90","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX\u00ae with and without Bone Mineral Density. Calcif Tissue Int. 2012;90(1):1\u201313.","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"2181_CR239","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bone.2004.08.018","volume":"36","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, J\u00f6nsson B. Intervention thresholds for osteoporosis in the UK. Bone. 2005;36(1):22\u201332.","journal-title":"Bone."},{"issue":"1","key":"2181_CR240","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00198-020-05594-8","volume":"32","author":"WD Leslie","year":"2021","unstructured":"Leslie WD, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, et al. Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. Osteoporos Int. 2021;32(1):113\u201322.","journal-title":"Osteoporos Int."},{"issue":"5","key":"2181_CR241","first-page":"Cd004523","volume":"5","author":"GA Wells","year":"2022","unstructured":"Wells GA, Hsieh SC, Zheng C, Peterson J, Tugwell P, Liu W. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2022;5(5):Cd004523.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"2181_CR242","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s002239900679","volume":"65","author":"J Parkkari","year":"1999","unstructured":"Parkkari J, Kannus P, Palvanen M, Natri A, Vainio J, Aho H, et al. Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: a prospective controlled hip fracture study with 206 consecutive patients. Calcified tissue international. 1999;65(3):183\u20137.","journal-title":"Calcified tissue international."},{"issue":"16","key":"2181_CR243","doi-asserted-by":"publisher","first-page":"E485","DOI":"10.1503\/cmaj.180115","volume":"190","author":"C Symonds","year":"2018","unstructured":"Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ. 2018;190(16):E485.","journal-title":"CMAJ."},{"issue":"2","key":"2181_CR244","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190\u20138.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2181_CR245","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018;29(12):2623\u201337.","journal-title":"Osteoporos Int."},{"issue":"1","key":"2181_CR246","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11657-020-00809-1","volume":"15","author":"MS Wilton-Clark","year":"2020","unstructured":"Wilton-Clark MS, Feasel AL, Kline GA, Billington EO. Autonomy begets adherence: decisions to start and persist with osteoporosis treatment after group medical consultation. Arch Osteoporos. 2020;15(1):138.","journal-title":"Arch Osteoporos."},{"issue":"2","key":"2181_CR247","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28(2):138\u201344.","journal-title":"Int J Technol Assess Health Care."},{"issue":"1","key":"2181_CR248","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12874-019-0782-0","volume":"19","author":"S Waffenschmidt","year":"2019","unstructured":"Waffenschmidt S, Knelangen M, Sieben W, B\u00fchn S, Pieper D. Single screening versus conventional double screening for study selection in systematic reviews: a methodological systematic review. BMC Med Res Methodol. 2019;19(1):132.","journal-title":"BMC Med Res Methodol."}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-023-02181-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T02:53:26Z","timestamp":1702090406000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-023-02181-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":248,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1186\/s13643-023-02181-w","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"18 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MG is an employee of the Canadian Agency for Drugs and Technologies in Health (CADTH). The current work was unrelated to her employment and CADTH had no role in the funding, design, or oversight of the work. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}